GlassScriptPhysician profile
Brian L Gerhardstein
NPI 1790982064
$5,035.04
in general payments reported to CMS, 2019-2025
36 companies · $1,616 in 2025
The $1,616 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,006 · 2023: $1,398 · 2024: $1,015 · 2025: $1,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,029.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,072.01 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $889.24 | 2022-2025 | |
| Pfizer INC. | $390.23 | 2023-2025 | |
| Lundbeck LLC | $314.75 | 2022-2025 | Vyepti, Rexulti |
| Biogen, INC. | $284.48 | 2022-2025 | Vumerity, Avonex, Plegridy |
| Lilly USA, LLC | $269.70 | 2022-2025 | Emgality, Reyvow, Kisunla |
| Teva Pharmaceuticals USA, INC. | $204.75 | 2022-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Ucb, INC. | $196.42 | 2022-2025 | Briviact, Nayzilam |
| Celgene Corporation | $184.91 | 2022-2025 | Zeposia |
| Argenx US, INC. | $134.95 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $130.74 | 2022-2025 | |
| Sk Life Science, INC. | $116.73 | 2022-2025 | |
| Amgen INC. | $98.07 | 2022 | |
| Amneal Pharmaceuticals LLC | $95.07 | 2022-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Impel Pharmaceuticals INC. | $89.66 | 2022-2023 | Trudhesa |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $66.06 | 2022-2025 | Ocrevus Zunovo |
| Axsome Therapeutics, INC. | $65.14 | 2025 | Symbravo |
| Biohaven Pharmaceutical Holding Company LTD. | $61.84 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $39.47 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $32.49 | 2023-2024 | Ultomiris |
| Neurelis, INC. | $31.57 | 2025 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $29.45 | 2023 | Nuedexta |
| Ge Healthcare | $25.20 | 2023 | |
| Mallinckrodt Hospital Products INC. | $24.57 | 2025 | Acthar |
| Cycle Pharmaceuticals INC | $18.88 | 2024 | Tascenso Odt |
| Tg Therapeutics, INC. | $18.82 | 2025 | |
| Otter Pharmaceuticals, LLC | $16.71 | 2025 | Sympazan |
| Aucta Pharmaceuticals, INC. | $16.38 | 2025 | Motpoly Xr |
| Janssen Pharmaceuticals, INC | $16.15 | 2022 | |
| Genzyme Corporation | $16.11 | 2023 | |
| Averitas Pharma INC. | $14.56 | 2025 | Qutenza |
| Kyowa Kirin, INC. | $14.35 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.21 | 2022 | |
| Collegium Pharmaceutical, INC. | $13.97 | 2022 | |
| Emd Serono, INC. | $13.82 | 2022 | |
| Alnylam Pharmaceuticals INC. | $13.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Gerhardstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.